Celebrated medicines can still take years to reach patients in some markets. These are documented, public timelines, presented as fact, not judgment.
Marketed in Europe under a different brand name. Sources: FiercePharma, 2024; Vertex company statements.
One of the most talked about gene therapies of recent years gained regulatory approval across roughly 37 European countries, yet only about 32 established a reimbursement pathway. In some markets, early access ran through managed programs while price and reimbursement were still being negotiated.
Sources: company disclosures and market access reporting, 2024 to 2025.
Approval is not access. The days between the two are real, they differ sharply by market, and they are rarely measured on purpose. Across Europe the median wait sits at 532 days.